CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Millions	Mar. 29, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 4,134	$ 4,009
Short-term investments	1,813	1,561
Accounts receivable, less allowances of $165 and $173	8,455	8,191
Inventories	5,224	4,978
Contract assets, net	1,366	1,435
Other current assets	2,387	1,964
Total current assets	23,378	22,137
Property, plant and equipment, net	9,331	9,306
Acquisition-related intangible assets, net	15,323	15,533
Other assets	4,516	4,492
Goodwill	46,493	45,853
Total assets	99,041	97,321
Current liabilities:
Short-term obligations and current maturities of long-term obligations	2,819	2,214
Accounts payable	3,049	3,079
Accrued payroll and employee benefits	1,419	1,988
Contract liabilities	2,866	2,852
Other accrued expenses	3,022	3,199
Total current liabilities	13,174	13,332
Deferred income taxes	1,041	1,268
Other long-term liabilities	3,971	3,989
Long-term obligations	31,370	29,061
Redeemable noncontrolling interest	128	120
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued	0	0
Common stock, $1 par value, 1,200,000,000 shares authorized; 444,246,082 and 443,841,240 shares issued	444	444
Capital in excess of par value	18,111	17,962
Retained earnings	54,447	53,102
Treasury stock at cost, 66,752,170 and 63,066,906 shares	(21,269)	(19,226)
Accumulated other comprehensive income/(loss)	(2,343)	(2,697)
Total Thermo Fisher Scientific Inc. shareholders’ equity	49,390	49,584
Noncontrolling interests	(33)	(33)
Total equity	49,357	49,551
Total liabilities, redeemable noncontrolling interest and equity	$ 99,041	$ 97,321